Erik Mayer

Biochemistry, Genetics and Molecular Biology · Life Sciences

57h-index23.0kcitations414works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(40), Surgical Simulation and Training(28), Patient Satisfaction in Healthcare(22), Cancer Treatment and Pharmacology(21), Prostate Cancer Diagnosis and Treatment(20)

Publications364 total

DEVELOPMENT OF A NEXT GENERATION ENGINEERED LIVE MICROBIOME BIOTHERAPEUTIC, E COLI NISSLE 1917-TTR, FOR ULCERATIVE COLITIS
Inflammatory Bowel Diseases·2026
The impact of primary care networks on emergency hospitalisations in the English NHS: An interrupted time series analysis
Health Policy·2025Open Access
Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by <scp>HBsAg</scp> Levels: A Cross‐Sectional Study
Journal of Viral Hepatitis·2025Open Access
Key factors behind the adoption of a patient-facing technology in primary care: a structured approach to variable importance
Health Services and Outcomes Research Methodology·2025Open Access
Hepatitis B Virus ( <scp>HBV</scp> ) Treatment Eligibility in the <scp>UK</scp> : Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines
Journal of Viral Hepatitis·2025· 2 citedOpen Access
Understanding the Clinical Characteristics and Timeliness of Diagnosis for Patients Diagnosed With Long Covid: A Retrospective Observational Cohort Study From North West London
Health Expectations·2025· 1 citedOpen Access
Acute Reactivity of Individuals With High and Low Levels of Ongoing Stress
Biopsychosocial Science and Medicine·2025
Translation without substitution: the need for responsible AI integration in patient instructions
BMJ Quality & Safety·2025Open Access
ABO blood group antigens influence host–microbe interactions and risk of early spontaneous preterm birth
npj Biofilms and Microbiomes·2025· 4 citedOpen Access
Sex-based associations between neighborhood disadvantage and brain–gut alterations in individuals with irritable bowel syndrome
Biology of Sex Differences·2025Open Access
Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial
Breast Cancer Research and Treatment·2025
Therapy de‐escalation for testicular cancer (THERATEST): A multi‐centre observational cohort feasibility study of de‐escalation therapies for good prognosis stage II germ cell tumours
BJUI Compass·2025Open Access
Improving transparency in data access processes: Developing best practice standards and promoting system-wide change through a competitive funding call
International Journal for Population Data Science·2025Open Access
Digitalization of Access to Primary Care: Is There an Equity‐Efficiency Trade‐Off?
Health Economics·2025Open Access
Understanding and Addressing Challenges With Electronic Health Record Use in Gynecological Oncology: Cross-Sectional Survey of Multidisciplinary Professionals in the United Kingdom and Co-Design of an Integrated Informatics Platform to Support Clinical Decision-Making
JMIR Cancer·2025· 1 citedOpen Access
The acceptability, feasibility, and perceived effectiveness of video-based patient records for supporting care delivery to older adults with frailty: a non-randomized mixed-methods pilot study (Preprint)
2025
Systematic curation and analysis of ovarian cancer data across multiple electronic record systems held within the UK National Health Service: a tertiary referral centre experience
ESMO Real World Data and Digital Oncology·2025Open Access
Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent <i>ESR1</i> mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.
Journal of Clinical Oncology·2025· 14 cited
Preventing the risk of tuberculosis with teriflunomide: Is pre-treatment screening necessary?
Therapies·2025
Management of Testicular Cancer
JCO Oncology Practice·2025· 5 cited
page 1 of 19Next →

Frequent Co-authors

Ara Darzi(29), Thanos Athanasiou(9), Justin Vale(7), Nick Sevdalis(6), Philip Pratt(6), Alex Bottle(5), Archie Hughes‐Hallett(5), Colin S. Cooper(4), Rosalind A. Eeles(4), David C. Wedge(4), Peter Van Loo(4), Gunes Gundem(4), Bárbara Kremeyer(4), Andy G. Lynch(4), Niedzica Camacho(4), Hayley J. Luxton(4), Sandra E. Edwards(4), Zsofia Kote‐Jarai(4), Nening M. Dennis(4), Jorge Zamora(4)